Russell Investments Group Ltd. Grows Stock Holdings in Smith & Nephew SNATS, Inc. $SNN

Key Points

• Russell Investments Group Ltd. increased its stake in Smith & Nephew SNATS by 20.4% during the first quarter, owning 283,483 shares valued at approximately $8.04 million.
• Smith & Nephew SNATS will pay a semi-annual dividend of $0.285 per share on November 7, with a reported dividend yield of 210.0%.
• Recent analyst reports show a consensus rating of "Hold" for Smith & Nephew SNATS, with a price target increase to $36.00 from various investment firms.

Russell Investments Group Ltd. boosted its holdings in Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 20.4% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 283,483 shares of the medical equipment provider's stock after acquiring an additional 48,043 shares during the quarter. Russell Investments Group Ltd. owned 0.06% of Smith & Nephew SNATS worth $8,042,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Hara Capital LLC lifted its position in shares of Smith & Nephew SNATS by 391.4% during the 4th quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider's stock worth $60,000 after buying an additional 1,957 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Smith & Nephew SNATS during the 4th quarter worth approximately $4,992,000. Barclays PLC bought a new position in shares of Smith & Nephew SNATS during the 4th quarter worth approximately $431,000. Mariner LLC lifted its position in shares of Smith & Nephew SNATS by 53.0% during the 4th quarter. Mariner LLC now owns 64,146 shares of the medical equipment provider's stock worth $1,577,000 after buying an additional 22,218 shares in the last quarter. Finally, First Trust Advisors LP bought a new position in shares of Smith & Nephew SNATS during the 4th quarter worth approximately $248,000. Institutional investors own 25.64% of the company's stock.

Analyst Upgrades and Downgrades

SNN has been the topic of several recent analyst reports. HSBC cut shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research report on Friday, April 25th. Hsbc Global Res cut shares of Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Wall Street Zen cut shares of Smith & Nephew SNATS from a "strong-buy" rating to a "buy" rating in a research report on Friday. Finally, Canaccord Genuity Group raised their price target on shares of Smith & Nephew SNATS from $28.00 to $36.00 and gave the stock a "hold" rating in a research note on Monday, August 18th. Six research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $36.00.

Smith & Nephew SNATS Stock Performance

Shares of SNN stock traded up $0.5630 during trading hours on Friday, hitting $37.5330. 603,940 shares of the company were exchanged, compared to its average volume of 984,738. Smith & Nephew SNATS, Inc. has a 52-week low of $23.69 and a 52-week high of $37.58. The stock has a market capitalization of $16.44 billion, a price-to-earnings ratio of 17.38, a P/E/G ratio of 1.02 and a beta of 0.68. The company has a current ratio of 3.00, a quick ratio of 1.40 and a debt-to-equity ratio of 0.60. The firm has a fifty day simple moving average of $31.96 and a 200 day simple moving average of $29.22.

Smith & Nephew SNATS Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Friday, November 7th. Investors of record on Friday, October 3rd will be paid a $0.285 dividend. This represents a yield of 210.0%. The ex-dividend date is Friday, October 3rd. Smith & Nephew SNATS's payout ratio is currently 26.39%.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.